AU6425699A - Methods of inhibiting platelet activation and recruitment - Google Patents

Methods of inhibiting platelet activation and recruitment

Info

Publication number
AU6425699A
AU6425699A AU64256/99A AU6425699A AU6425699A AU 6425699 A AU6425699 A AU 6425699A AU 64256/99 A AU64256/99 A AU 64256/99A AU 6425699 A AU6425699 A AU 6425699A AU 6425699 A AU6425699 A AU 6425699A
Authority
AU
Australia
Prior art keywords
recruitment
methods
platelet activation
inhibiting platelet
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64256/99A
Inventor
Richard B. Gayle III
Charles R. Maliszewski
Aaron J. Marcus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Cornell Research Foundation Inc
Original Assignee
Immunex Corp
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp, Cornell Research Foundation Inc filed Critical Immunex Corp
Publication of AU6425699A publication Critical patent/AU6425699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
AU64256/99A 1998-10-16 1999-10-13 Methods of inhibiting platelet activation and recruitment Abandoned AU6425699A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10458598P 1998-10-16 1998-10-16
US60104585 1998-10-16
US10746698P 1998-11-06 1998-11-06
US60107466 1998-11-06
US14901099P 1999-08-13 1999-08-13
US60149010 1999-08-13
PCT/US1999/023641 WO2000023094A2 (en) 1998-10-16 1999-10-13 Methods of inhibiting platelet activation and recruitment

Publications (1)

Publication Number Publication Date
AU6425699A true AU6425699A (en) 2000-05-08

Family

ID=27379766

Family Applications (2)

Application Number Title Priority Date Filing Date
AU64256/99A Abandoned AU6425699A (en) 1998-10-16 1999-10-13 Methods of inhibiting platelet activation and recruitment
AU64115/99A Ceased AU772460B2 (en) 1998-10-16 1999-10-13 Inhibitors of platelet activation and recruitment

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU64115/99A Ceased AU772460B2 (en) 1998-10-16 1999-10-13 Inhibitors of platelet activation and recruitment

Country Status (7)

Country Link
EP (1) EP1123306A4 (en)
JP (1) JP2002527096A (en)
AU (2) AU6425699A (en)
CA (1) CA2345382A1 (en)
IL (1) IL142539A0 (en)
NZ (1) NZ511488A (en)
WO (2) WO2000023094A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264809B1 (en) 1998-10-16 2007-09-04 Immunex Corporation Methods of inhibiting platelet activation and recruitment
JP5550799B2 (en) 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド TWEAK antagonists and TWEAK receptor antagonists and their use to treat immunological disorders
GB9914326D0 (en) * 1999-06-18 1999-08-18 Rademacher Group Limited Materials and methods relating to the diagnosis and treatment of pre-eclampsia
EP1305342A2 (en) * 2000-07-24 2003-05-02 Attenuon, LLC Human kininogen d5 domain polypeptides and their use
MY128992A (en) * 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen
AU2002361763A1 (en) * 2001-12-17 2003-06-30 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
ATE441706T1 (en) 2002-02-20 2009-09-15 Gen Hospital Corp BIODEGRADABLE POLYMER CONJUGATES AND USE THEREOF
DK1997512T3 (en) 2002-04-09 2014-01-27 Biogen Idec Inc Methods for treating TWEAK-related conditions
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
CA2498651C (en) 2002-09-13 2011-08-30 Universite Laval Nucleoside triphosphate diphosphohydrolase and uses thereof
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
US7390485B2 (en) 2004-02-27 2008-06-24 Apt Therapeutics, Inc. Design and therapeutic use of adpase enhanced apyrases
CA2597945C (en) 2005-02-17 2016-07-12 Biogen Idec Ma Inc. Treating neurological disorders
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
DK1888113T3 (en) * 2005-05-27 2014-09-01 Biogen Idec Inc TWEAK BINDING ANTIBODIES
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
DE102006046410A1 (en) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Medicaments for the prophylaxis or treatment or diagnosis of ischemic diseases
GB201522541D0 (en) * 2015-12-21 2016-02-03 Inst Research In Biomedicine Compositions
CN108203457B (en) * 2016-12-20 2022-09-06 山西医科大学 Antithrombotic small peptide omega KWR for targeted inhibition of platelet aggregation
EP3424957A1 (en) * 2017-07-03 2019-01-09 advanceCOR GmbH Fusion protein
UY38299A (en) 2018-07-18 2020-02-28 Novartis Ag SOLUBILIZED APIRASES, METHODS AND USES
WO2024023746A1 (en) * 2022-07-29 2024-02-01 Novartis Ag Improved production of cd39 variants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
CU22222A1 (en) * 1989-08-03 1995-01-31 Cigb PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP0815252A1 (en) * 1995-03-24 1998-01-07 Novartis AG Gene therapy for transplantation and inflammatory or thrombotic conditions
WO1996032471A2 (en) * 1995-04-10 1996-10-17 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology

Also Published As

Publication number Publication date
WO2000023094A2 (en) 2000-04-27
EP1123306A4 (en) 2002-07-03
WO2000023459A1 (en) 2000-04-27
AU6411599A (en) 2000-05-08
CA2345382A1 (en) 2000-04-27
IL142539A0 (en) 2002-03-10
AU772460B2 (en) 2004-04-29
WO2000023094A3 (en) 2000-07-27
JP2002527096A (en) 2002-08-27
EP1123306A1 (en) 2001-08-16
NZ511488A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
AU6425699A (en) Methods of inhibiting platelet activation and recruitment
AU3300599A (en) Per-method designation of security requirements
IL128739A0 (en) Inhibition of blood platelet aggregation
AU7710198A (en) Single pass lead and method of use
AU3768799A (en) Isoquinoline compound melanocortin receptor ligands and methods of using same
AU9035898A (en) Electrosurgical systems and methods for the removal of pacemaker leads
AU2785399A (en) Preparation of polyindanebisphenols and polymers derived therefrom
AU4919496A (en) Potentiators of antibacterial agents
AU2872795A (en) Inhibition of platelet binding
AU1616499A (en) Chemokine variants and methods of use
AU2098799A (en) Method of inhibiting interleukin-12 signaling
AU4822499A (en) Making particulates of controlled dimensions
AU6457398A (en) Odorizer or freshener article and method of making the same
AU3552697A (en) Novel treatment of leptine resistance
AU5399096A (en) Combination compositions containing benazepril or benazeprilat and valsartan
AU4636199A (en) Method of reducing or preventing malodour
AU4841499A (en) Human transferases
AU6270799A (en) Firestarter and method of making same
AU1919699A (en) Micro-catheters and methods of their manufacture
AU2997099A (en) Methods of suppressing microglial activation
EP0721780A3 (en) Agent for promoting platelet and/or leukocyte production
AU9569998A (en) Photo-spectrometers, methods of use and manufacture
PL342733A1 (en) Biocement of improved properties
AU1812601A (en) Cover member and method of making same
AU5131699A (en) Cryogranulation of activated protein c

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase